Source-grounded facts extracted from Zenas BioPharma, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Zenas BioPharma, Inc. shareholders approved Ratification of appointment of Ernst & Young LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-12-31 meeting.
“Proposal Two : The stockholders ratified the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2026, based on the following votes: For Against Abstain 52,654,975 7,650 3,496”
Zenas BioPharma, Inc. shareholders approved Election of two Class II directors to serve for three-year terms.
“Proposal One : The stockholders elected each of the two nominees listed below as Class II directors to serve on the Company’s Board of Directors for a term of three years expiring at the Company’s 2029 Annual Meeting of Stockholders and until their successors are duly elected and qualified, based on the following votes: Director Nominee For Against Abstain Broker Non-Votes James Boylan 44,083,930 4,121,508 2,499 4,458,184 Patrick Enright 44,253,715 3,951,474 2,748 4,458,184”
Zenas BioPharma, Inc. reported financial results for the quarter ended March 31, 2026.
“On May 13, 2026, Zenas BioPharma, Inc. issued a press release announcing its financial results for the quarter ended March 31, 2026.”
Tomas Kiselak resigned as director at Zenas BioPharma, Inc..
“Tomas Kiselak did not stand for re-election at the expiration of his term ending at the Annual Meeting, and, accordingly, as of the conclusion of the Annual Meeting Mr. Kiselak’s term ended with his resignation from the Board of Directors of the Company, and the size of the Board of Directors was reduced by one.”
Zenas BioPharma, Inc. incurred convertible notes of $200,000,000 aggregate principal amount with U.S. Bank Trust Company, National Association at 2.50% per year maturing April 1, 2032.
“On March 31, 2026, Zenas BioPharma, Inc. (the “Company”) completed its public offering (the “Convertible Notes Offering”) of $200,000,000 aggregate principal amount of its 2.50% Convertible Senior Notes due 2032 (the “Notes”).”
Zenas BioPharma, Inc. entered into Indenture with U.S. Bank Trust Company, National Association valued at $200,000,000 aggregate principal amount (effective 2026-03-31).
“Completed its public offering (the “Convertible Notes Offering”) of $200,000,000 aggregate principal amount of its 2.50% Convertible Senior Notes due 2032 (the “Notes”). The Notes were issued pursuant to, and are governed by, an indenture (the “Base Indenture”), dated as of March 31, 2026, between the Company and U.S. Bank Trust Company, National Association, as trustee (the “Trustee”), as supplemented by a first supplemental indenture (the “Supplemental Indenture,” and the Base Indenture, as supplemented by the Supplemental Indenture, the “Indenture”), dated as of March 31, 2026, between the Company and the Trustee.”
Zenas BioPharma, Inc. reported financial results for the quarter and year ended December 31, 2025.
“Zenas BioPharma, Inc. issued a press release announcing its financial results for the quarter and year ended December 31, 2025.”
Ting (Tim) Xiao resigned as Director at Zenas BioPharma, Inc..
“Ting (Tim) Xiao did not stand for re-election at the expiration of his term ending at the Annual Meeting, and, accordingly, as of the conclusion of the Annual Meeting Mr. Xiao’s term ended with his resignation from the Board of Directors of the Company”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.